According to filings with the U.S. Securities and Exchange Commission, Alida Biosciences is raising up to $8,520,384.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Gudrun Stengel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alida Biosciences
Alida Bio is pioneering technology for next-generation epigenetic analysis that will empower a new wave of research, therapeutics, and diagnostics. Epigenetic markers, including modifications of DNA, RNA and histone proteins, work in concert to control how the genetic code is used in health and disease. Unlike current methods that detect single modifications one at a time, our technology accurately detects and locates many epigenetic markers simultaneously. The epitranscriptome encompasses all naturally occurring chemical modifications of RNA. While our understanding of the epitranscriptome is still incomplete, there is ample evidence for a critical role of RNA modifications, including vital functions in cancer progression, drug resistance, cell differentiation and viral infection. Our mission is to create innovative technology for reading of the epitranscriptome.

To learn more about Alida Biosciences, visit http://alidabio.com/
Company Linkedin Page: https://www.linkedin.com/company/alida-biosciences/

Contact:
Gudrun Stengel, President and Chief Executive Officer
720-375-1071
https://www.linkedin.com/in/gudrun-stengel-b2a59126/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.